Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Arvinas in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($0.50) per share for the quarter. The consensus estimate for Arvinas' current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas' Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.79) EPS, FY2025 earnings at ($2.89) EPS and FY2026 earnings at ($3.53) EPS.
ARVN has been the topic of several other research reports. Oppenheimer boosted their price target on shares of Arvinas from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday. HC Wainwright reissued a "buy" rating and issued a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Wedbush reaffirmed an "outperform" rating and set a $57.00 price objective on shares of Arvinas in a report on Tuesday. BTIG Research started coverage on Arvinas in a research note on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price objective on the stock. Finally, Guggenheim restated a "buy" rating and set a $57.00 target price on shares of Arvinas in a research report on Wednesday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Arvinas has a consensus rating of "Moderate Buy" and an average price target of $59.58.
Read Our Latest Research Report on ARVN
Arvinas Price Performance
Shares of ARVN traded down $0.28 on Monday, reaching $17.67. 1,055,284 shares of the stock traded hands, compared to its average volume of 913,193. The stock's 50-day moving average price is $19.04 and its 200-day moving average price is $23.28. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -3.78 and a beta of 1.88. Arvinas has a 12 month low of $16.61 and a 12 month high of $53.08.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. During the same period last year, the company earned ($2.53) EPS.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Arvinas by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company's stock valued at $135,389,000 after acquiring an additional 56,561 shares in the last quarter. FMR LLC increased its holdings in shares of Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company's stock valued at $71,023,000 after purchasing an additional 204,317 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Arvinas by 18.7% in the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock valued at $57,371,000 after purchasing an additional 367,343 shares in the last quarter. New Leaf Venture Partners L.L.C. raised its position in Arvinas by 10.5% in the 4th quarter. New Leaf Venture Partners L.L.C. now owns 1,585,721 shares of the company's stock worth $30,398,000 after purchasing an additional 151,000 shares during the last quarter. Finally, Braidwell LP lifted its holdings in Arvinas by 148.3% during the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company's stock worth $31,637,000 after buying an additional 767,242 shares in the last quarter. 95.19% of the stock is owned by institutional investors.
About Arvinas
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Articles
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
